67 results about "Eye infection" patented technology

The invention provides an ophthalmic, otic or nasal pharmaceutical composition, comprising levofloxacin or the pharmaceutical acceptable salts thereof and loteprednol etabonate, wherein the weight ratio of loteprednol etabonate to levofloxacin is 1:0.2-5. The use of ophthalmic, otic or nasal pharmaceutical composition of the invention in preparation of the medication for treatment of conjunctivitis, keratitis, blepharitis, dacrycystitis, hordeolum, corneal ulcer and ocular infection accompanied with ophthalmitis and even inflammation of the surrounding tissues, to prevent increase of bacterial infection risks and the tissue inflammation of the infected area after the ophthalmic surgeries or ocular injuries, to treat or alleviate the bacterial infection in combination with the tissue inflammation of the infected area, or to treat tympanitis, otitis externa and infective rhinitis.

The invention provides compositions and methods of treating an ocular condition by administering to an eye of a patient having an ocular condition an effective amount of a catechin or polyphenol. The compositions and methods can be used to treat ocular conditions such as ocular infection, ocular inflammation, ocular cancer or benign eye tumors.

The invention features methods and compositions for treating ocular infections. The method comprises topically administering to an eye of an animal in need of such treatment an ocular infection-treating amount of azithromycin.

A preservative-free opthalmic composition for treating eye infections is disclosed. The composition contains a quinolone compound in an amount effective as an antibiotic when the composition is placed in the eye. The composition is rendered isoosmotic with polyhydric alcohol. The composition may be utilized to treat ophthalmic conditions by topically applying the composition to the affected tissues.

An ocular Jiatishaxing gel for treating eyelid inflammation, stye, conjunctivitis, dacryocystitis, keratitis, corneal ulcer and trachoma is prepared from Jiatishaxing, HPMC as matrix, antiseptic, isotonic regulator, osmotic promoter, pH regulator and water through dissolving Jiatishaxing in water, adding others, stirring, regulating pH=5-9, filter and adding water.

An antimicrobial composition and methods of use are provided. The antimicrobial composition includes a water-soluble antimicrobial organosilane ammonium compound and a sugar. The composition may be in liquid, foam, ointment or gel form. The composition may include anti-inflammatory medications, alcohol and/or steroids. The antimicrobial composition may be used to treat eye infections in humans and animals. The antimicrobial composition may be applied directly to the surface of the eye. The antimicrobial composition may further be used to treat ocular related articles, including contact lenses, contact cases, instruments, pads and the like. The antimicrobial composition may be applied directly to the surface of the ocular related article during and/or after manufacture.

The invention discloses lomefloxacin hydrochloride eye drops and a preparation method and application thereof. The lomefloxacin accounts for 0.3% of the active components. The preparation also comprises a tackifier, a buffer salt system, a wetting agent, an isoosmotic adjusting agent, a pH adjusting agent and a bacteriostatic agent, and is suitable for treating the external eye infections such asacute and chronic bacterial conjunctivitis, blepharitis, hordeolum, meibomiantis, dacryocystitis, keratitis, keratohelcosis and the like caused by sensitive pathogenic bacteria. The product is characterized in that: by adding the sodium hyaluronate with a tackifying effect and a moisturizing effect, the viscosity of the lomefloxacin hydrochloride eye drops is improved, the fluidics property thereof is changed, the residence time of the eye drops in the eyes is prolonged, the sufficient absorption of the medicine is ensured, the bioavailability is increased, the administration times are reduced, the compliance of a patient is improved, and an effective treatment effect is realized.

The invention relates to a gel for lysozyme eye and a preparation method thereof. The gel for the lysozyme eye is applicable of treating various normal eye infection diseases, such as a pinkeye, an ophthalmia, a ceratitis, a keratohelcosis, a conjunctivitis and the like, which is caused by bacteria, Chlamydia, virus and drug-resistance bacteria. The gel for the lysozyme eye disclosed by the invention uses a solution containing 0.1-10.0% of lysozyme, 0.01-20% of water soluble macromolecule matrix, 0.1-10% of a pH modifier, 0.01-10% of a bacteriostat and 0.1-10% of a viscosity modifier and takes a solution with a pH value of 5.0-6.5 as a buffer solution. With the adoption of the receipt of the gel for the lysozyme eye provided by the invention, the time that drug lysozyme remains on an eye can be prolonged, and the bacteriostat efficiency of the lysozyme on the eye can be improved.

Eye drapes that cover the conjunctiva and reduce the incidence of eye infection are provided. The eye drape has a flexible material and attached thereto a surgical drape. The flexible material is preferably circular with an opening to expose the cornea. The bottom of the flexible material is preferably convex relative to the shape of the eye. The outer diameter of the flexible material is conveniently fits over the ball of the eye. The surgical drape has an opening greater than or equal to the inner diameter and smaller than or equal to the outer diameter of the flexible material. The flexible material is removably fixed to the eye through a vacuum force caused by air expelled from, e.g. (i) a pocket of air in between the flexible material and the eye, (ii) a chamber with openings at the bottom of the flexible material, and/or (iii) a suction device.

The present invention relates to novel 17,20-dihydrofusidic acid derivatives (Ia) for use in pharmaceutical compositions for the treatment of infections, in particular topical compositions for the treatment of skin infections or eye infections.

In some aspects, pegylated aminoglycoside compounds are provided. In some embodiments, m-PEG-tobramycin compounds may be used to treat a biofilm infection or reduce or treat established biofilms. The present invention provides, in various aspects, compounds and methods for the treatment of infections, such as biofilm infections or chronic biofilm infections. The chronic biofilm infection may occur in wounds, implanted devices, immunocompromised patients, people with cystic fibrosis, eye infections, etc.

The invention provides an uliflourxacin eye drop and a preparation method thereof. The uliflourxacin eye drop is directly prepared from uliflourxacin as a raw material, and per ml of uliflourxacin contains 1-5mg and auxiliary materials suitable for an eye drop preparation or injection water. The uliflourxacin eye drop provided by the invention is capable of effectively preventing and treating eye infection of sensitive bacteria, especially infection of Gram-negative bacteria including pseudomonas aeruginosa with increasing drug resistance, is high in bioavailability, long in standing time in eyes, remarkable in post-antibiotic effect, beneficial to reduction of a single dose of a drug, good in treatment effect, and low in cost; the preparation method is simple and convenient, is short in period, meets the large-scale production need, and has a practical significance for treating eye infectious diseases increasingly resisting drug.

The invention discloses an eye drop which mainly contains amikacin or amikacin salt and chitosan or the derivative of chitosan. The eye drop comes into being through the dissolving of a medicine compound into the injection water which is then added with leakage pressure adjusting agent, pH value adjusting agent, acid-bases buffer, chemical inhibitor and bacteriostatic agent, then the addition of the full dose of injection water after the dissolving, then the filtering and sterilization of the solution, with the finished product obtained finally after the canning and sealing. The invention, on one hand, reduces the dosage of amikacin through the coordinate antibacterial action of chitosan, the derivative of chitosan and the amikacin, thus reducing the toxic and side effect and particularly reducing the toxicity to ears and kidneys. On the other hand, the invention prolongs the time for which the medicine stays in the eyes through taking advantage of the solution with a certain viscosity obtained after the dissolving of chitosan and the derivative of chitosan into the water, thus improving the use efficiency of the medicine, reducing the medicine using times and prolonging the intervals for medicine using. The invention has a good result in curing the eye infection caused by sensitive bacteria, such as conjunctivitis, keratitis, sclerotitis, etc.

Provided here are new ophthalmologically suitable pharmaceutical compositions comprising an effective amount of gatifloxacin, prednisolone, and bromfenac. In aspects, the compositions are suspensions that include a suspension component comprising one or more suspension agents. In aspects, the suspension component includes an ionic suspension agent. In aspects, the composition also or alternatively comprises a non-ionic surfactant, non-ionic suspension agent, or both, or an agent that provides both functions. In aspects, such compositions further comprise an effective amount of a chelating agent/component. Further described are related compositions and methods of making and using such compositions, e.g., in the treatment of eye infections.